Brief: Orchard Announces FDA Regenerative Medicine Advanced Therapy Designation Granted For OTL-103 For Treatment Of Wiskott-Aldrich Syndrome
29/07/2019 12:21
July 29 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS ANNOUNCES FDA REGENERATIVE MEDICINE
ADVANCED THERAPY (RMAT) DESIGNATION GRANTED FOR OTL-103 FOR THE
TREATMENT OF WISKOTT-ALDRICH SYNDROME
* ORCHARD THERAPEUTICS PLC - REGULATORY SUBMISSIONS PLANNED
IN
U.S. AND EUROPE FOR 2021 FOR OTL-103
* ORCHARD THERAPEUTICS PLC - THREE-YEAR REGISTRATIONAL DATA
SET
TO BE PRESENTED BY YEAR END 2019 FOR OTL-103
Source text for Eikon: ID:nGNX87TtD1
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln